{"DataElement":{"publicId":"4474278","version":"1","preferredName":"Patient Strong CYP3A CYP2C8 Induction Inhibition Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The yes/no/not applicable coded response regarding whether a patient received strong inhibitors and/or inductors of cytochrome P450.","longName":"STR_P450_IND_INH_COD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"4473475","version":"1","preferredName":"Patient Strong CYP3A CYP2C8 Induction Inhibition Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Having strength, power, or intensity greater than average or expected._Human CYP3A gene locus is located within 7q21.3-q22.1 and is approximately 218 kb in length. This locus includes four protein-encoding genes, CYP3A4, CYP3A5, CYP3A7 and CYP3A43, and two pseudogenes, CYP3A5P1 and CYP3A5P2. The protein-encoding genes are involved in drug metabolism and the biosynthesis of cholesterol, steroids and other lipids._This gene plays a role in drug metabolism. It is also involved in the oxidation of both endobiotics and xenobiotics._The act of bringing about something._The interference with or prevention of an action or response even though the stimulus for that action or response is present._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:4473473v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4473473","version":"1","preferredName":"Strong CYP3A Gene Locus CYP2C8 Gene Induction Inhibition Clinical Trial Eligibility Criteria","preferredDefinition":"Having strength, power, or intensity greater than average or expected.:Human CYP3A gene locus is located within 7q21.3-q22.1 and is approximately 218 kb in length. This locus includes four protein-encoding genes, CYP3A4, CYP3A5, CYP3A7 and CYP3A43, and two pseudogenes, CYP3A5P1 and CYP3A5P2. The protein-encoding genes are involved in drug metabolism and the biosynthesis of cholesterol, steroids and other lipids.:This gene plays a role in drug metabolism. It is also involved in the oxidation of both endobiotics and xenobiotics.:The act of bringing about something.:The interference with or prevention of an action or response even though the stimulus for that action or response is present.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"4473473v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Strong","conceptCode":"C62223","definition":"Having strength, power, or intensity greater than average or expected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"CYP3A Gene Locus","conceptCode":"C107557","definition":"Human CYP3A gene locus is located within 7q21.3-q22.1 and is approximately 218 kb in length. This locus includes four protein-encoding genes, CYP3A4, CYP3A5, CYP3A7 and CYP3A43, and two pseudogenes, CYP3A5P1 and CYP3A5P2. The protein-encoding genes are involved in drug metabolism and the biosynthesis of cholesterol, steroids and other lipids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"CYP2C8 Gene","conceptCode":"C46071","definition":"This gene plays a role in drug metabolism. It is also involved in the oxidation of both endobiotics and xenobiotics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Induction","conceptCode":"C61367","definition":"The act of bringing about something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Inhibition","conceptCode":"C42791","definition":"The interference with or prevention of an action or response even though the stimulus for that action or response is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"022C94FC-EFD2-2F3F-E050-BB89AD434900","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"ONEDATA","dateModified":"2014-09-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"022C94FC-EFE3-2F3F-E050-BB89AD434900","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9343_Theradex_ghd_09.03.14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000083","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"}]}],"AlternateNames":[{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"Theradex","type":"USED_BY","context":"Theradex"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"STRG_IND_INH_CD_IND","type":"OID, Theradex","context":"Theradex"}],"ReferenceDocuments":[{"name":"Is patient receiving any medi","type":"Preferred Question Text","description":"Is patient receiving any medications or substances that are strong inhibitors or inducers of CYP3A or CYP2C8?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Is patient receiving concurrent use of strong CYP3A inhibitors such as ketoconazole, itraconazole, voriconazole, posaconazole, nefazodone, and clarithromycin are not allowed less than or equal to 7 days prior to registration?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Is patient receiving any medications or substances that are strong inhibitors or inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Does patient require any medications or substances that are strong or moderate CYP3A inhibitors or clinically significant enzyme inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Is patient receiving any medications or substances that are strong inducers/inhibitors or substrates of CYP3A4/5, CYP2C9, CYP2C8, or CYP2C19?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Is patient receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 or moderate inhibitors of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Is patient currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inhibitors of CYP3A4 (at least 1 week prior) and potent inducers of CYP3A4 (at least 3 week prior)?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Is patient currently receiving (or is unable to stop use at least 1 week prior to receiving the 1st dose of AZD9291) medications or herbal supplements known to be potent inhibitors of CYP2C8 and potent inhibitors or inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Is patient receiving any medications or substances that are inhibitors or inducers of cytochrome P450 3A (CYP3A4 enzyme)?","url":null,"context":"Theradex"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Chronic concomitant treatment with strong CYP2C8 inhibitor(s)","url":null,"context":"Alliance"},{"name":"CRF Text 2","type":"Alternate Question Text","description":"If used, will CYP3A4 inhibitors and inducers be discontinued within two weeks prior to the start of study treatment and for the duration of treatment with copanlisib?","url":null,"context":"NRG"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Is patient receiving concomitant medications with strong inhibitors or inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Is patient receiving treatment with strong inhibitors and/or inducers of cytochrome P450 (CYP) 3A4, CYP2C19 or CYP2C19 within 1 week preceding the first dose of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Does patient require the chronic use of medications or substances that are strong inhibitors or inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Does patient require concurrent treatment with any medications or substances that are potent inhibitors or inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Is patient receiving any medications or substances that are potent inhibitors or inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Is patient currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 week prior)?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Has patient taken (or received) any known CYP3A4 substrates with narrow therapeutic window (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfanide) within the 14 days prior to receiving the first dose of KRT-232 (AMG 232)?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Is the patient receiving any medications or substances that are strong inhibitors and/or strong or moderate inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Is patient receiving any known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) within 2 weeks of cycle 1 day 1, moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) within 1 week, strong CYP3A inducers (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) within 4 weeks prior to cycle 1 day 1  or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil)?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Has patient been treated with inhibitors or inducers of CYP3A that are prohibited from 14 days prior to the first dose of tazemetostat to the end of study?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Is patient receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 within 2 weeks prior to start of and during treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Is patient taking medications that are strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir) and strong inducers of CYP3A4 (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort from 14 days prior to enrollment until the end of the study?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Is patient currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 week prior)?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Is patient receiving strong CYP3A4/5 inducers or inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Is patient using (concurrently) strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and/or strong inducers of CYP3A4 (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) from 14 days prior to enrollment until the end of the study?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Is patient taking medications that are strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir) and strong inducers of CYP3A4 (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) from 14 days prior to enrollment until the end of the study?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Is patient receiving strong CYP2A4/5 inducers or inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Is patient receiving any medications or substances that are inhibitors or inducers of CYP3A?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Is patient receiving strong or moderate CYP3A4/5 inducers or inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Is patient receiving concomitant administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir) or inducers of CYP3A4 (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Is patient receiving concomitant administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir) or inducers of CYP3A4 (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort)?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Is patient receiving or requires strong inducers or strong inhibitors of CYP3A4, strong inhibitors of CYP1A2, or CYP3A4 substrates which have a narrow therapeutic range within 2 weeks of the first dose of study treatment (3 weeks for St. John's wort)?","url":null,"context":"Theradex"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Does the patient have concomitant use of known strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g., bosentan, efavirenz, modafmil)?","url":null,"context":"NRG"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Is patient currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 week prior)?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Does patient require chronic administration of any medications or substances that are strong inhibitors or inducers of CYP3A4 enzyme?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Does patient require any medications or substances that are strong inhibitors or inducers of CYP3A during the course of the study?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Is patient receiving concomitant strong CYP3A inhibitors or inducers, as noted in section 3.3.5?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Has patient received any medications or substances that are strong or moderate inhibitors or inducers of CYP3A less than or equal to 14 days prior to study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Has patient taken strong CYP3A4 inhibitors or strong CYP3A4 inducers or consumed grapefruit or its juice, or other fruit/juices which are strong CYP3A4 inhibitors within 2 weeks prior to start of study treatment?","url":null,"context":"Theradex"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Is the patient receiving drugs with a narrow therapeutic range that are sensitive substrates CYP2C8, 2C9, 2C19, 2D6, or 1A2?","url":null,"context":"COG"},{"name":"COG CRF Text 100","type":"Alternate Question Text","description":"Is the patient receiving drugs with a narrow therapeutic range that are sensitive substrates of Cytochrome P450 (CYP) enzymes?","url":null,"context":"COG"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Is patient taking any known CYP3A4 substrates with narrow therapeutic window (such as alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, sirolimus, or terfanide) within the 14 days prior to receiving the first dose of AMG 232?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Is patient receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 and they cannot be transferred to alternative medication?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Has patient currently been treated with a prohibited medication (i.e. medications or substances that are strong inhibitors or inducers of CYP3A or CYP2C8) within 13 days prior to the first treatment through the end of the study?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Is patient receiving any medications or substances that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 and cannot be transferred to alternative medication?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Is patient receiving potent CYP3A4-inhibiting agents?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Does patient require treatment with strong/moderate CYP3A inhibitors or inducers?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Is patient receiving any medications or substances that are inhibitors or inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Has patient received known moderate or strong CYP3A inducers within 7 days of enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Is patient receiving any medications or substances that are strong inhibitors or strong inducers of CYP3A4 or substrates of CYP1A2 with narrow therapeutic windows?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Is patient receiving any medications or substances that are strong inhibitors or inducers of CYP3A4?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Is patient receiving treatment with strong inhibitors or inducers of CYP3A4 or P-glycoprotein within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Has patient currently been treated with a prohibited medication (i.e. medications or substances that are strong or moderate inhibitors or inducers of CYP3A or strong inhibitors or inducers of CYP2C8) within 14 days prior to the first treatment through the end of the study?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Is patient taking concomitant strong inhibitors of CYP3A4/5 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir) or strong inducers of CYP3A4/5 (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) from 14 days prior to enrollment until the end of the study?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Has patient received strong inhibitors or inducers of CYP3A4 at least 7 days prior to the first dose of APG-1252 and cobimetinib?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Will patient be receiving a strong CYP3A4 inhibitor antifungal prophylaxis (posaconazole, voriconazole) starting on Day 4 of induction (after completion of anthracycline) and continue on it during duration of induction, reinduction (if needed) and consolidation cycle (see section 3.2.5 of protocol)?","url":null,"context":"Theradex"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Is patient currently receiving, or has received in last 14 days, any medications or substances that are considered moderate or strong inhibitors or inducers of CYP3A4/5, not including those allowed per protocol?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0230001B-0545-B07D-E050-BB89AD432E50","latestVersionIndicator":"Yes","beginDate":"2014-09-03","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-09-03","modifiedBy":"SOKKERL","dateModified":"2024-01-08","changeDescription":"9343_Theradex_ghd_09.03.14 - Changed Theradex Text 32 from \"Application Standard Question Text\" to \"Alternate Question Text\"","administrativeNotes":"7/21/23 removed special characters from AQTs_mmt\r\n2023.6.22 AQT added per ticket request CADSR0002541. ak 8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"}}